Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Decreases By 37.2%

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant decline in short interest in September. As of September 15th, there was short interest totaling 77,600 shares, a decline of 37.2% from the August 31st total of 123,500 shares. Currently, 5.2% of the shares of the company are short sold. Based on an average daily volume of 690,300 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 690,300 shares, the short-interest ratio is presently 0.1 days. Currently, 5.2% of the shares of the company are short sold.

Avalon GloboCare Stock Down 0.4%

NASDAQ:ALBT opened at $2.24 on Friday. The business’s 50-day simple moving average is $2.33 and its two-hundred day simple moving average is $3.13. Avalon GloboCare has a 52 week low of $1.87 and a 52 week high of $11.66. The stock has a market cap of $8.60 million, a PE ratio of -0.11 and a beta of 0.03.

Avalon GloboCare (NASDAQ:ALBT) last released its earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million during the quarter.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Saturday, September 27th. Wall Street Zen lowered shares of Avalon GloboCare to a “strong sell” rating in a report on Saturday, September 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.